Cara Therapeutics' (NASDAQ:CARA) stock has been on a tear following news that Vifor Fresenius Medical Care Renal Pharma Ltd. licensed certain ex-U.S. rights to Korsuva, Cara Therapeutics' treatment for chronic kidney disease-associated itching in dialysis patients.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,